Subcutaneous homograft tumor growth of B-HLA-E plus/hPD-L1 MC38 cells. B-HLA-E plus/hPD-L1 MC38 cells (5x10⁵) and wild-type MC38 cells (5x10⁵) were subcutaneously implanted into C57BL/6 mice (female, 8-week-old). Tumor volume and body weight were measured twice a week. (A) Average tumor volume ± SEM. (B)  Body weight (Mean± SEM). Volume was expressed in mm³ using the formula: V=0.5 X long diameter X short diameter². As shown in panel A, B-HLA-E plus/hPD-L1 MC38 cells were able to establish tumors in vivo and can be used for efficacy studies.

B-HLA-E plus/hPD-L1 MC38 cells were subcutaneously transplanted into C57BL/6 mice (n=6), and on 35 days post inoculation, tumor cells were harvested and assessed for human PD-L1 and HLA-E expression by FACS. As shown, human PD-L1 and HLA-E  were highly expressed by tumor cells. Therefore, B-HLA-E plus/hPD-L1 MC38 cells can be used for in vivo efficacy studies.

Subcutaneous homograft tumor growth of B-HLA-E plus/hPD-L1 MC38 cells. B-HLA-E plus/hPD-L1 MC38 cells (5x10⁵) were subcutaneously implanted into B-hPD-1/hPD-L1/hCD94/hNKG2A mice (female, 8-week-old, n=5). Tumor volume and body weight were measured twice a week. (A) Average tumor volume ± SEM. (B)  Body weight (Mean± SEM). Volume was expressed in mm³ using the formula: V=0.5 X long diameter X short diameter². As shown in panel A, B-HLA-E plus/hPD-L1 MC38 cells were able to establish tumors in vivo and can be used for efficacy studies.

Protein expression analysis of tumor cells

B-HLA-E plus/hPD-L1 MC38 cells were subcutaneously transplanted into B-hPD-1/hPD-L1/hCD94/hNKG2A mice (n=6), and on 31 days post inoculation, tumor cells were harvested and assessed for human PD-L1 and HLA-E expression by FACS. As shown, HLA-E and human PD-L1 were highly expressed by tumor cells. Therefore, B-HLA-E plus/hPD-L1 MC38 cells can be used for in vivo efficacy studies.